Skip to main content
OpenTrials
Completed

NCT Number: NCT00559182

A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)

This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK-8033.

Parts A and B of the study will determine the maximum tolerated dose (MTD) and RP2D. Part C of the study will be a single panel crossover study to determine the effect of omeprazole, a gastric pH modifier, on the pharmacokinetics of MK-8033.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must be at least 18 years of age, with adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance of <2
  • Patient must be willing to undergo pre-study and post-dose tumor biopsy and have tumor accessible for biopsy (Waived during Parts A and C)

Exclusion criteria

  • Patient is currently using bisphosphonate therapy or has received this therapy in past 6 months
  • Patient has had chemotherapy, radiotherapy, or biological therapy within 4 weeks of study participation
  • Patient has history of cardiac disease
  • Patient with a primary central nervous system tumor
  • Patient has a known psychiatric or substance abuse disorder
  • Patient is pregnant or breastfeeding, or expecting to conceive during the study
  • Patient is known to be Human Immunodeficiency Virus (HIV) positive and the HIV infection is not well controlled
  • Patient has received therapy with a Proton-Pump Inhibitor, Histamine2-Receptor antagonist or antacid within one week of study participation (Part B only)

Treatment and study plan

Comparator: MK-8033

Drug

MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at ~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).

Enrollment in Parts A and B has been completed.

Comparator: MK-8033 +/- omeprazole

Drug

Part C will occur at only one of the investigational sites.

In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.

Enrollment for Part C has been suspended.

Primary outcomes

  1. Safety and tolerability of MK-8033 based on drug-related dose limiting toxicity.

    Time frame: for the entire duration of study (27 months)

  2. Recommended Phase II Dose (RP2D) based on safety, tumor pharmacodynamics, and pharmacokinetics

    Time frame: for the entire duration of study (27 months)

  3. Plasma area under the curve (AUC) for F2 formulation alone or in combination with omeprazole

    Time frame: Day 1-21

  4. Safety and tolerability of MK-8033 F2 formulation alone or in combination with omeprazole based on incidence of adverse experiences

    Time frame: Day 1-21

  5. Tumor Pharmacodynamics (PD): phospho-c-Met (MET or MNNG HOS Transforming gene) Levels (Parts A & B)

    Time frame: Cycle 1 pre-dose & Day 12

  6. Tumor PD: phospho-Akt (Protein Kinase B) Levels (Parts A & B)

    Time frame: Cycle 1 pre-dose & Day 12

  7. Tumor PD: phospho-MAPK (mitogen-activated protein kinase) Levels (Parts A & B)

    Time frame: Cycle 1 pre-dose & Day 12

  8. Bone PD: Cross-Linked N-telopeptides of Type I collagen (NTx) Levels (Parts A & B)

    Time frame: Baseline, Cycle 1 Day 8, & Cycle 3 Day 1

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Phase I Dose Escalation Study of MK-8033 in Patients With Advanced Solid Tumors

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Nov 16, 2007
Registry last updated
Jul 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.